131 results on '"Chamoun, Mira"'
Search Results
2. 14-3-3 ζ/δ-reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2
- Author
-
Woo, Marcel S., Nilsson, Johanna, Therriault, Joseph, Rahmouni, Nesrine, Brinkmalm, Ann, Benedet, Andrea L., Ashton, Nicholas J., Macedo, Arthur C., Servaes, Stijn, Wang, Yi-Ting, Tissot, Cécile, Arias, Jaime Fernandez, Hosseini, Seyyed Ali, Chamoun, Mira, Lussier, Firoza Z., Karikari, Thomas K., Stevenson, Jenna, Mayer, Christina, Ferrari-Souza, João Pedro, Kobayashi, Eliane, Massarweh, Gassan, Friese, Manuel A., Pascoal, Tharick A., Gauthier, Serge, Zetterberg, Henrik, Blennow, Kaj, and Rosa-Neto, Pedro
- Published
- 2023
- Full Text
- View/download PDF
3. Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer’s disease
- Author
-
Cassidy, Clifford M., Therriault, Joseph, Pascoal, Tharick A., Cheung, Victoria, Savard, Melissa, Tuominen, Lauri, Chamoun, Mira, McCall, Adelina, Celebi, Seyda, Lussier, Firoza, Massarweh, Gassan, Soucy, Jean-Paul, Weinshenker, David, Tardif, Christine, Ismail, Zahinoor, Gauthier, Serge, and Rosa-Neto, Pedro
- Published
- 2022
- Full Text
- View/download PDF
4. Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
- Author
-
Nilsson, Johanna, Ashton, Nicholas J., Benedet, Andrea L., Montoliu-Gaya, Laia, Gobom, Johan, Pascoal, Tharick A., Chamoun, Mira, Portelius, Erik, Jeromin, Andreas, Mendes, Muriel, Zetterberg, Henrik, Rosa-Neto, Pedro, Brinkmalm, Ann, and Blennow, Kaj
- Published
- 2022
- Full Text
- View/download PDF
5. Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
- Author
-
Pascoal, Tharick A., Chamoun, Mira, Lax, Elad, Wey, Hsiao-Ying, Shin, Monica, Ng, Kok Pin, Kang, Min Su, Mathotaarachchi, Sulantha, Benedet, Andrea L., Therriault, Joseph, Lussier, Firoza Z., Schroeder, Frederick A., DuBois, Jonathan M., Hightower, Baileigh G., Gilbert, Tonya M., Zürcher, Nicole R., Wang, Changning, Hopewell, Robert, Chakravarty, Mallar, Savard, Melissa, Thomas, Emilie, Mohaddes, Sara, Farzin, Sarah, Salaciak, Alyssa, Tullo, Stephanie, Cuello, A. Claudio, Soucy, Jean-Paul, Massarweh, Gassan, Hwang, Heungsun, Kobayashi, Eliane, Hyman, Bradley T., Dickerson, Bradford C., Guiot, Marie-Christine, Szyf, Moshe, Gauthier, Serge, Hooker, Jacob M., and Rosa-Neto, Pedro
- Published
- 2022
- Full Text
- View/download PDF
6. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
- Author
-
Pascoal, Tharick A., Chamoun, Mira, Lax, Elad, Wey, Hsiao-Ying, Shin, Monica, Ng, Kok Pin, Kang, Min Su, Mathotaarachchi, Sulantha, Benedet, Andrea L., Therriault, Joseph, Lussier, Firoza Z., Schroeder, Frederick A., DuBois, Jonathan M., Hightower, Baileigh G., Gilbert, Tonya M., Zürcher, Nicole R., Wang, Changning, Hopewell, Robert, Chakravarty, Mallar, Savard, Melissa, Thomas, Emilie, Mohaddes, Sara, Farzin, Sarah, Salaciak, Alyssa, Tullo, Stephanie, Cuello, A. Claudio, Soucy, Jean-Paul, Massarweh, Gassan, Hwang, Heungsun, Kobayashi, Eliane, Hyman, Bradley T., Dickerson, Bradford C., Guiot, Marie-Christine, Szyf, Moshe, Gauthier, Serge, Hooker, Jacob M., and Rosa-Neto, Pedro
- Published
- 2022
- Full Text
- View/download PDF
7. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
- Author
-
Simrén, Joel, Brum, Wagner S., Ashton, Nicholas J., Benedet, Andrea L., Karikari, Thomas K., Kvartsberg, Hlin, Sjons, Emma, Lussier, Firoza Z., Chamoun, Mira, Stevenson, Jenna, Hopewell, Robert, Pallen, Vanessa, Ye, Keqiang, Pascoal, Tharick A., Zetterberg, Henrik, Rosa-Neto, Pedro, and Blennow, Kaj
- Published
- 2022
- Full Text
- View/download PDF
8. Microglial activation and tau propagate jointly across Braak stages
- Author
-
Pascoal, Tharick A., Benedet, Andrea L., Ashton, Nicholas J., Kang, Min Su, Therriault, Joseph, Chamoun, Mira, and Savard, Melissa
- Subjects
Tau proteins -- Health aspects -- Physiological aspects ,Alzheimer's disease -- Diagnosis -- Development and progression ,Biological sciences ,Health - Abstract
Compelling experimental evidence suggests that microglial activation is involved in the spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the hypothesis that the spatial propagation of microglial activation and tau accumulation colocalize in a Braak-like pattern in the living human brain. We studied 130 individuals across the aging and AD clinical spectrum with positron emission tomography brain imaging for microglial activation ([.sup.11C]PBR28), amyloid-[beta] (A[beta]) ([.sup.18F]AZD4694) and tau ([.sup.18F]MK-6240) pathologies. We further assessed microglial triggering receptor expressed on myeloid cells 2 (TREM2) cerebrospinal fluid (CSF) concentrations and brain gene expression patterns. We found that [.sup.11C]PBR28 correlated with CSF soluble TREM2 and showed regional distribution resembling TREM2 gene expression. Network analysis revealed that microglial activation and tau correlated hierarchically with each other following Braak-like stages. Regression analysis revealed that the longitudinal tau propagation pathways depended on the baseline microglia network rather than the tau network circuits. The co-occurrence of A[beta], tau and microglia abnormalities was the strongest predictor of cognitive impairment in our study population. Our findings support a model where an interaction between A[beta] and activated microglia sets the pace for tau spread across Braak stages. Microglial activation and tau accumulation propagate together in patients with Alzheimer's disease, suggesting an interaction that determines disease progression., Author(s): Tharick A. Pascoal [sup.1] [sup.2] [sup.3] [sup.4] , Andrea L. Benedet [sup.3] , Nicholas J. Ashton [sup.5] [sup.6] [sup.7] , Min Su Kang [sup.3] [sup.4] , Joseph Therriault [sup.3] [...]
- Published
- 2021
- Full Text
- View/download PDF
9. 14-3-3 $$\upzeta /\updelta$$-reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2
- Author
-
Woo, Marcel S., primary, Nilsson, Johanna, additional, Therriault, Joseph, additional, Rahmouni, Nesrine, additional, Brinkmalm, Ann, additional, Benedet, Andrea L., additional, Ashton, Nicholas J., additional, Macedo, Arthur C., additional, Servaes, Stijn, additional, Wang, Yi-Ting, additional, Tissot, Cécile, additional, Arias, Jaime Fernandez, additional, Hosseini, Seyyed Ali, additional, Chamoun, Mira, additional, Lussier, Firoza Z., additional, Karikari, Thomas K., additional, Stevenson, Jenna, additional, Mayer, Christina, additional, Ferrari-Souza, João Pedro, additional, Kobayashi, Eliane, additional, Massarweh, Gassan, additional, Friese, Manuel A., additional, Pascoal, Tharick A., additional, Gauthier, Serge, additional, Zetterberg, Henrik, additional, Blennow, Kaj, additional, and Rosa-Neto, Pedro, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
- Author
-
Benedet, Andréa L., Ashton, Nicholas J., Pascoal, Tharick A., Leuzy, Antoine, Mathotaarachchi, Sulantha, Kang, Min S., Therriault, Joseph, Savard, Melissa, Chamoun, Mira, Schöll, Michael, Zimmer, Eduardo R., Gauthier, Serge, Labbe, Aurélie, Zetterberg, Henrik, Blennow, Kaj, and Neto, Pedro R.
- Published
- 2019
- Full Text
- View/download PDF
11. Publisher Correction: Microglial activation and tau propagate jointly across Braak stages
- Author
-
Pascoal, Tharick A., Benedet, Andrea L., Ashton, Nicholas J., Kang, Min Su, Therriault, Joseph, Chamoun, Mira, Savard, Melissa, Lussier, Firoza Z., Tissot, Cécile, Karikari, Thomas K., Ottoy, Julie, Mathotaarachchi, Sulantha, Stevenson, Jenna, Massarweh, Gassan, Schöll, Michael, de Leon, Mony J., Soucy, Jean-Paul, Edison, Paul, Blennow, Kaj, Zetterberg, Henrik, Gauthier, Serge, and Rosa-Neto, Pedro
- Published
- 2021
- Full Text
- View/download PDF
12. Plasma pTau‐217 and N‐terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid‐β positive individuals.
- Author
-
Woo, Marcel S., Tissot, Cécile, Lantero‐Rodriguez, Juan, Snellman, Anniina, Therriault, Joseph, Rahmouni, Nesrine, Macedo, Arthur C., Servaes, Stijn, Wang, Yi‐Ting, Arias, Jaime Fernandez, Hosseini, Seyyed Ali, Chamoun, Mira, Lussier, Firoza Z., Benedet, Andrea L., Ashton, Nicholas J., Karikari, Thomas K., Triana‐Baltzer, Gallen, Kolb, Hartmuth C., Stevenson, Jenna, and Mayer, Christina
- Abstract
INTRODUCTION: We set out to identify tau PET‐positive (A+T+) individuals among amyloid‐beta (Aβ) positive participants using plasma biomarkers. METHODS: In this cross‐sectional study we assessed 234 participants across the AD continuum who were evaluated by amyloid PET with [18F]AZD4694 and tau‐PET with [18F]MK6240 and measured plasma levels of total tau, pTau‐181, pTau‐217, pTau‐231, and N‐terminal tau (NTA‐tau). We evaluated the performances of plasma biomarkers to predict tau positivity in Aβ+ individuals. RESULTS: Highest associations with tau positivity in Aβ+ individuals were found for plasma pTau‐217 (AUC [CI95%] = 0.89 [0.82, 0.96]) and NTA‐tau (AUC [CI95%] = 0.88 [0.91, 0.95]). Combining pTau‐217 and NTA‐tau resulted in the strongest agreement (Cohen's Kappa = 0.74, CI95% = 0.57/0.90, sensitivity = 92%, specificity = 81%) with PET for classifying tau positivity. DISCUSSION: The potential for identifying tau accumulation in later Braak stages will be useful for patient stratification and prognostication in treatment trials and in clinical practice. Highlights: We found that in a cohort without pre‐selection pTau‐181, pTau‐217, and NTA‐tau showed the highest association with tau PET positivity.We found that in Aβ+ individuals pTau‐217 and NTA‐tau showed the highest association with tau PET positivity.Combining pTau‐217 and NTA‐tau resulted in the strongest agreement with the tau PET‐based classification. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
- Author
-
Therriault, Joseph, primary, Lussier, Firoza Z., additional, Tissot, Cécile, additional, Chamoun, Mira, additional, Stevenson, Jenna, additional, Rahmouni, Nesrine, additional, Pallen, Vanessa, additional, Bezgin, Gleb, additional, Servaes, Stijn, additional, Kunach, Peter, additional, Wang, Yi‐Ting, additional, Fernandez‐Arias, Jaime, additional, Vermeiren, Marie, additional, Pascoal, Tharick A., additional, Massarweh, Gassan, additional, Vitali, Paolo, additional, Soucy, Jean‐Paul, additional, Saha‐Chaudhuri, Paramita, additional, Gauthie, Serge, additional, and Rosa‐Neto, Pedro, additional
- Published
- 2023
- Full Text
- View/download PDF
14. Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer’s disease
- Author
-
Fernández Arias, Jaime, primary, Therriault, Joseph, additional, Thomas, Emilie, additional, Lussier, Firoza Z, additional, Bezgin, Gleb, additional, Tissot, Cécile, additional, Servaes, Stijn, additional, Mathotaarachchi, Sulantha S, additional, Schoemaker, Dorothée, additional, Stevenson, Jenna, additional, Rahmouni, Nesrine, additional, Kang, Min Su, additional, Pallen, Vanessa, additional, Poltronetti, Nina Margherita, additional, Wang, Yi-Ting, additional, Kunach, Peter, additional, Chamoun, Mira, additional, Quispialaya S, Kely M, additional, Vitali, Paolo, additional, Massarweh, Gassan, additional, Gauthier, Serge, additional, Rajah, Maria N, additional, Pascoal, Tharick, additional, and Rosa-Neto, Pedro, additional
- Published
- 2023
- Full Text
- View/download PDF
15. Characterization of an automated method to segment the human locus coeruleus
- Author
-
Sibahi, Ahmad, primary, Gandhi, Rushali, additional, Al‐Haddad, Rami, additional, Therriault, Joseph, additional, Pascoal, Tharick, additional, Chamoun, Mira, additional, Boutin‐Miller, Krysta, additional, Tardif, Christine, additional, Rosa‐Neto, Pedro, additional, and Cassidy, Clifford M., additional
- Published
- 2023
- Full Text
- View/download PDF
16. APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
- Author
-
Ferrari-Souza, João Pedro, primary, Lussier, Firoza Z., additional, Leffa, Douglas T., additional, Therriault, Joseph, additional, Tissot, Cécile, additional, Bellaver, Bruna, additional, Ferreira, Pâmela C. L., additional, Malpetti, Maura, additional, Wang, Yi-Ting, additional, Povala, Guilherme, additional, Benedet, Andréa L., additional, Ashton, Nicholas J., additional, Chamoun, Mira, additional, Servaes, Stijn, additional, Bezgin, Gleb, additional, Kang, Min Su, additional, Stevenson, Jenna, additional, Rahmouni, Nesrine, additional, Pallen, Vanessa, additional, Poltronetti, Nina Margherita, additional, O’Brien, John T., additional, Rowe, James B., additional, Cohen, Ann D., additional, Lopez, Oscar L., additional, Tudorascu, Dana L., additional, Karikari, Thomas K., additional, Klunk, William E., additional, Villemagne, Victor L., additional, Soucy, Jean-Paul, additional, Gauthier, Serge, additional, Souza, Diogo O., additional, Zetterberg, Henrik, additional, Blennow, Kaj, additional, Zimmer, Eduardo R., additional, Rosa-Neto, Pedro, additional, and Pascoal, Tharick A., additional
- Published
- 2023
- Full Text
- View/download PDF
17. Aβ-induced vulnerability propagates via the brain’s default mode network
- Author
-
Pascoal, Tharick A., Mathotaarachchi, Sulantha, Kang, Min Su, Mohaddes, Sara, Shin, Monica, Park, Ah Yeon, Parent, Maxime J., Benedet, Andrea L., Chamoun, Mira, Therriault, Joseph, Hwang, Heungsun, Cuello, A. Claudio, Misic, Bratislav, Soucy, Jean-Paul, Aston, John A. D., Gauthier, Serge, and Rosa-Neto, Pedro
- Published
- 2019
- Full Text
- View/download PDF
18. Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
- Author
-
Pascoal, Tharick A., primary, Leuzy, Antoine, additional, Therriault, Joseph, additional, Chamoun, Mira, additional, Lussier, Firoza, additional, Tissot, Cecile, additional, Strandberg, Olof, additional, Palmqvist, Sebastian, additional, Stomrud, Erik, additional, Ferreira, Pamela C. L., additional, Ferrari‐Souza, João Pedro, additional, Smith, Ruben, additional, Benedet, Andrea Lessa, additional, Gauthier, Serge, additional, Hansson, Oskar, additional, and Rosa‐Neto, Pedro, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Medial temporal tau predicts memory decline in cognitively unimpaired elderly
- Author
-
Kwan, Angela T H, primary, Arfaie, Saman, additional, Therriault, Joseph, additional, Azizi, Zahra, additional, Lussier, Firoza Z, additional, Tissot, Cecile, additional, Chamoun, Mira, additional, Bezgin, Gleb, additional, Servaes, Stijn, additional, Stevenon, Jenna, additional, Rahmouni, Nesrine, additional, Pallen, Vanessa, additional, Gauthier, Serge, additional, and Rosa-Neto, Pedro, additional
- Published
- 2022
- Full Text
- View/download PDF
20. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions
- Author
-
Tissot, Cécile, primary, Servaes, Stijn, additional, Lussier, Firoza Z., additional, Ferrari-Souza, João Pedro, additional, Therriault, Joseph, additional, Ferreira, Pâmela C.L., additional, Bezgin, Gleb, additional, Bellaver, Bruna, additional, Leffa, Douglas Teixeira, additional, Mathotaarachchi, Sulantha S., additional, Chamoun, Mira, additional, Stevenson, Jenna, additional, Rahmouni, Nesrine, additional, Kang, Min Su, additional, Pallen, Vanessa, additional, Margherita-Poltronetti, Nina, additional, Wang, Yi-Ting, additional, Fernandez-Arias, Jaime, additional, Benedet, Andrea L., additional, Zimmer, Eduardo R., additional, Soucy, Jean-Paul, additional, Tudorascu, Dana L., additional, Cohen, Annie D., additional, Sharp, Madeleine, additional, Gauthier, Serge, additional, Massarweh, Gassan, additional, Lopresti, Brian, additional, Klunk, William E., additional, Baker, Suzanne L., additional, Villemagne, Victor L., additional, Rosa-Neto, Pedro, additional, and Pascoal, Tharick A., additional
- Published
- 2022
- Full Text
- View/download PDF
21. Additional file 1 of CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
- Author
-
Simrén, Joel, Brum, Wagner S., Ashton, Nicholas J., Benedet, Andrea L., Karikari, Thomas K., Kvartsberg, Hlin, Sjons, Emma, Lussier, Firoza Z., Chamoun, Mira, Stevenson, Jenna, Hopewell, Robert, Pallen, Vanessa, Ye, Keqiang, Pascoal, Tharick A., Zetterberg, Henrik, Rosa-Neto, Pedro, and Blennow, Kaj
- Abstract
Additional file 1: Supplementary figure 1. Baseline CSF tau368 concentrations. Supplementary figure 2. Correlation between CSF tau, cognition and tau PET with age. Supplementary figure 3. ROC curves for identifying Braak stages. Supplementary figure 4. Correlation between CSF tau biomarkers and hippocampal volume. Supplementary table 1. Correlation between CSF tau biomarkers and tau PET SUVr. Supplementary table 2. Correlations with tau PET imaging and cognition using ratios with p-tau in the group with symptomatic AD. Supplementary table 3. The relationship between CSF p-tau217 and PET imaging. Supplementary table 4. The relationship between CSF p-tau181 and PET imaging. Supplementary table 5. The relationship between CSF t-tau and PET imaging. Supplementary table 6. Correlation between global cognition and CSF biomarkers in the whole group.
- Published
- 2023
- Full Text
- View/download PDF
22. In vivo quantification of neurofibrillary tangles with [18F]MK-6240
- Author
-
Pascoal, Tharick A., Shin, Monica, Kang, Min Su, Chamoun, Mira, Chartrand, Daniel, Mathotaarachchi, Sulantha, Bennacef, Idriss, Therriault, Joseph, Ng, Kok Pin, Hopewell, Robert, Bouhachi, Reda, Hsiao, Hung-Hsin, Benedet, Andrea L., Soucy, Jean-Paul, Massarweh, Gassan, Gauthier, Serge, and Rosa-Neto, Pedro
- Published
- 2018
- Full Text
- View/download PDF
23. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions.
- Author
-
Tissot, Cécile, Servaes, Stijn, Lussier, Firoza Z., Pedro Ferrari-Souza, João, Therriault, Joseph, Ferreira, Pâmela C. L., Bezgin, Gleb, Bellaver, Bruna, Leffa, Douglas Teixeira, Mathotaarachchi, Sulantha S., Chamoun, Mira, Stevenson, Jenna, Rahmouni, Nesrine, Min Su Kang, Pallen, Vanessa, Margherita-Poltronetti, Nina, Yi-Ting Wang, Fernandez-Arias, Jaime, Benedet, Andrea L., and Zimmer, Eduardo R.
- Published
- 2023
- Full Text
- View/download PDF
24. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
- Author
-
Ashton, Nicholas J., primary, Benedet, Andréa L., additional, Pascoal, Tharick A., additional, Karikari, Thomas K., additional, Lantero-Rodriguez, Juan, additional, Brum, Wagner S., additional, Mathotaarachchi, Sulantha, additional, Therriault, Joseph, additional, Savard, Melissa, additional, Chamoun, Mira, additional, Stoops, Erik, additional, Francois, Cindy, additional, Vanmechelen, Eugeen, additional, Gauthier, Serge, additional, Zimmer, Eduardo R., additional, Zetterberg, Henrik, additional, Blennow, Kaj, additional, and Rosa-Neto, Pedro, additional
- Published
- 2022
- Full Text
- View/download PDF
25. Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET
- Author
-
Tissot, Cécile, primary, Therriault, Joseph, additional, Kunach, Peter, additional, L Benedet, Andréa, additional, Pascoal, Tharick A., additional, Ashton, Nicholas J., additional, Karikari, Thomas K., additional, Servaes, Stijn, additional, Lussier, Firoza Z., additional, Chamoun, Mira, additional, Tudorascu, Dana L., additional, Stevenson, Jenna, additional, Rahmouni, Nesrine, additional, Poltronetti, Nina Margherita, additional, Pallen, Vanessa, additional, Bezgin, Gleb, additional, Kang, Min Su, additional, Mathotaarachchi, Sulantha S., additional, Wang, Yi-Ting, additional, Fernandez Arias, Jaime, additional, Ferreira, Pamela Cristina Lukasewicz, additional, Ferrari-Souza, João Pedro, additional, Vanmechelen, Eugeen, additional, Blennow, Kaj, additional, Zetterberg, Henrik, additional, Gauthier, Serge, additional, and Rosa-Neto, Pedro, additional
- Published
- 2022
- Full Text
- View/download PDF
26. Additional file 1 of Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
- Author
-
Nilsson, Johanna, Ashton, Nicholas J., Benedet, Andrea L., Montoliu-Gaya, Laia, Gobom, Johan, Pascoal, Tharick A., Chamoun, Mira, Portelius, Erik, Jeromin, Andreas, Mendes, Muriel, Zetterberg, Henrik, Rosa-Neto, Pedro, Brinkmalm, Ann, and Blennow, Kaj
- Subjects
InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,ComputingMilieux_COMPUTERSANDEDUCATION ,Data_FILES ,ComputerApplications_COMPUTERSINOTHERSYSTEMS - Abstract
Additional file 1. Supplementary tables.
- Published
- 2022
- Full Text
- View/download PDF
27. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
- Author
-
Benedet, Andréa L., Milà-Alomà, Marta, Vrillon, Agathe, Ashton, Nicholas J., Pascoal, Tharick A., Lussier, Firoza, Karikari, Thomas K., Hourregue, Claire, Cognat, Emmanuel, Dumurgier, Julien, Stevenson, Jenna, Rahmouni, Nesrine, Pallen, Vanessa, Poltronetti, Nina M., Salvadó, Gemma, Shekari, Mahnaz, Operto, Gregory, Gispert, Juan Domingo, Minguillon, Carolina, Fauria, Karine, Kollmorgen, Gwendlyn, Suridjan, Ivonne, Zimmer, Eduardo R., Zetterberg, Henrik, Molinuevo, José Luis, Paquet, Claire, Rosa-Neto, Pedro, Blennow, Kaj, Suárez-Calvet, Marc, Beteta, Annabella, Cacciaglia, Raffaele, Cañas, Alba, Deulofeu, Carme, Cumplido, Irene, Dominguez, Ruth, Emilio, Maria, Falcon, Carles, Fuentes, Sherezade, Hernandez, Laura, Huesa, Gema, Huguet, Jordi, Marne, Paula, Menchón, Tania, Operto, Grégory, Polo, Albina, Pradas, Sandra, Soteras, Anna, Vilanova, Marc, Vilor-Tejedor, Natalia, Gaubert, Sinead, Lilamand, Matthieu, Hugon, Jacques, Indart, Sandrine, Fayel, Alexandra, Gmiz, Malika, Francisque, Hélène, Meauzoone, Aurélie, Martinet, Matthieu, Tence, Gabrielle, Chamoun, Mira, Therriault, Joseph, Tissot, Cécile, Bezgin, Gleb, Gauthier, Serge, Gagnon, Guilaine, and Stevensson, Alyssa
- Subjects
medicine.medical_specialty ,macromolecular substances ,Cohort Studies ,Cerebrospinal fluid ,Alzheimer Disease ,Internal medicine ,Glial Fibrillary Acidic Protein ,medicine ,Dementia ,Humans ,Online First ,Demència ,Aged ,Original Investigation ,Aged, 80 and over ,Glial fibrillary acidic protein ,biology ,business.industry ,Research ,Area under the curve ,Plasma sanguini ,Middle Aged ,medicine.disease ,Astrogliosis ,Alzheimer, Malaltia d' ,Endocrinology ,Cross-Sectional Studies ,nervous system ,Concomitant ,Marcadors bioquímics ,biology.protein ,Biomarker (medicine) ,Neurology (clinical) ,Alzheimer's disease ,business ,Biomarkers ,Comments - Abstract
Key Points Question What are the levels of plasma glial fibrillary acidic protein (GFAP) throughout the Alzheimer disease (AD) continuum, and how do they compare with the levels of cerebrospinal fluid (CSF) GFAP? Findings In this cross-sectional study, plasma GFAP levels were elevated in the preclinical and symptomatic stages of AD, with levels higher than those of CSF GFAP. Plasma GFAP had a higher accuracy than CSF GFAP to discriminate between amyloid-β (Aβ)–positive and Aβ-negative individuals, also at the preclinical stage. Meaning This study suggests that plasma GFAP is a sensitive biomarker that significantly outperforms CSF GFAP in indicating Aβ pathology in the early stages of AD., Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). However, it is not known whether there are differences in blood GFAP levels across the entire AD continuum and whether its performance is similar to that of CSF GFAP. Objective To evaluate plasma GFAP levels throughout the entire AD continuum, from preclinical AD to AD dementia, compared with CSF GFAP. Design, Setting, and Participants This observational, cross-sectional study collected data from July 29, 2014, to January 31, 2020, from 3 centers. The Translational Biomarkers in Aging and Dementia (TRIAD) cohort (Montreal, Canada) included individuals in the entire AD continuum. Results were confirmed in the Alzheimer’s and Families (ALFA+) study (Barcelona, Spain), which included individuals with preclinical AD, and the BioCogBank Paris Lariboisière cohort (Paris, France), which included individuals with symptomatic AD. Main Outcomes and Measures Plasma and CSF GFAP levels measured with a Simoa assay were the main outcome. Other measurements included levels of CSF amyloid-β 42/40 (Aβ42/40), phosphorylated tau181 (p-tau181), neurofilament light (NfL), Chitinase-3-like protein 1 (YKL40), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) and levels of plasma p-tau181 and NfL. Results of amyloid positron emission tomography (PET) were available in TRIAD and ALFA+, and results of tau PET were available in TRIAD. Results A total of 300 TRIAD participants (177 women [59.0%]; mean [SD] age, 64.6 [17.6] years), 384 ALFA+ participants (234 women [60.9%]; mean [SD] age, 61.1 [4.7] years), and 187 BioCogBank Paris Lariboisière participants (116 women [62.0%]; mean [SD] age, 69.9 [9.2] years) were included. Plasma GFAP levels were significantly higher in individuals with preclinical AD in comparison with cognitively unimpaired (CU) Aβ-negative individuals (TRIAD: Aβ-negative mean [SD], 185.1 [93.5] pg/mL, Aβ-positive mean [SD], 285.0 [142.6] pg/mL; ALFA+: Aβ-negative mean [SD], 121.9 [42.4] pg/mL, Aβ-positive mean [SD], 169.9 [78.5] pg/mL). Plasma GFAP levels were also higher among individuals in symptomatic stages of the AD continuum (TRIAD: CU Aβ-positive mean [SD], 285.0 [142.6] pg/mL, mild cognitive impairment [MCI] Aβ-positive mean [SD], 332.5 [153.6] pg/mL; AD mean [SD], 388.1 [152.8] pg/mL vs CU Aβ-negative mean [SD], 185.1 [93.5] pg/mL; Paris: MCI Aβ-positive, mean [SD], 368.6 [158.5] pg/mL; AD dementia, mean [SD], 376.4 [179.6] pg/mL vs CU Aβ-negative mean [SD], 161.2 [67.1] pg/mL). Plasma GFAP magnitude changes were consistently higher than those of CSF GFAP. Plasma GFAP more accurately discriminated Aβ-positive from Aβ-negative individuals than CSF GFAP (area under the curve for plasma GFAP, 0.69-0.86; area under the curve for CSF GFAP, 0.59-0.76). Moreover, plasma GFAP levels were positively associated with tau pathology only among individuals with concomitant Aβ pathology. Conclusions and Relevance This study suggests that plasma GFAP is a sensitive biomarker for detecting and tracking reactive astrogliosis and Aβ pathology even among individuals in the early stages of AD., This cross-sectional cohort study evaluates plasma glial fibrillary acidic protein levels throughout the entire Alzheimer disease continuum, from preclinical Alzheimer disease to Alzheimer disease dementia, compared with cerebrospinal fluid glial fibrillary acidic protein.
- Published
- 2021
28. Medial temporal tau predicts memory decline in cognitively unimpaired elderly.
- Author
-
Kwan, Angela T. H., Arfaie, Saman, Therriault, Joseph, Azizi, Zahra, Lussier, Firoza Z., Tissot, Cecile, Chamoun, Mira, Bezgin, Gleb, Servaes, Stijn, Stevenon, Jenna, Rahmouni, Nesrine, Pallen, Vanessa, Gauthier, Serge, and Rosa-Neto, Pedro
- Published
- 2023
- Full Text
- View/download PDF
29. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages
- Author
-
Pascoal, Tharick A, primary, Benedet, Andrea L, additional, Tudorascu, Dana L, additional, Therriault, Joseph, additional, Mathotaarachchi, Sulantha, additional, Savard, Melissa, additional, Lussier, Firoza Z, additional, Tissot, Cécile, additional, Chamoun, Mira, additional, Kang, Min Su, additional, Stevenson, Jenna, additional, Massarweh, Gassan, additional, Guiot, Marie-Christine, additional, Soucy, Jean-Paul, additional, Gauthier, Serge, additional, and Rosa-Neto, Pedro, additional
- Published
- 2021
- Full Text
- View/download PDF
30. Additional file 1 of Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
- Author
-
Tissot, Cécile, Benedet, Andréa L., Therriault, Joseph, Tharick A. Pascoal, Firoza Z. Lussier, Paramita Saha-Chaudhuri, Chamoun, Mira, Savard, Melissa, Sulantha S. Mathotaarachchi, Bezgin, Gleb, Wang, Yi-Ting, Arias, Jaime Fernandez, Rodriguez, Juan Lantero, Snellman, Anniina, Ashton, Nicholas J., Karikari, Thomas K., Blennow, Kaj, Zetterberg, Henrik, Villers-Sidani, Etienne De, Huot, Philippe, Gauthier, Serge, and Rosa-Neto, Pedro
- Abstract
Additional file 1: Supplementary Figure 1. Correlations maps (R-maps) of cross-sectional analyses, in both CU and CI groups. Supplementary Figure 2. Longitudinal changes of plasma pTau181 in each individual. Supplementary Figure 3. Longitudinal plasma pTau181 changes among cognitively unimpaired and cognitively impaired individuals, stratified by Aβ status.
- Published
- 2021
- Full Text
- View/download PDF
31. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer's disease.
- Author
-
Pascoal, Tharick A., Chamoun, Mira, Lax, Elad, Wey, Hsiao-Ying, Shin, Monica, Ng, Kok Pin, Kang, Min Su, Mathotaarachchi, Sulantha, Benedet, Andrea L., Therriault, Joseph, Lussier, Firoza Z., Schroeder, Frederick A., DuBois, Jonathan M., Hightower, Baileigh G., Gilbert, Tonya M., Zürcher, Nicole R., Wang, Changning, Hopewell, Robert, Chakravarty, Mallar, and Savard, Melissa
- Subjects
ALZHEIMER'S disease ,TAU proteins ,POSITRON emission tomography ,HISTONES ,HISTONE deacetylase ,CEREBRAL atrophy ,PATIENT-ventilator dyssynchrony ,FORENSIC pathology - Abstract
Alzheimer's disease (AD) is characterized by the brain accumulation of amyloid-β and tau proteins. A growing body of literature suggests that epigenetic dysregulations play a role in the interplay of hallmark proteinopathies with neurodegeneration and cognitive impairment. Here, we aim to characterize an epigenetic dysregulation associated with the brain deposition of amyloid-β and tau proteins. Using positron emission tomography (PET) tracers selective for amyloid-β, tau, and class I histone deacetylase (HDAC I isoforms 1–3), we find that HDAC I levels are reduced in patients with AD. HDAC I PET reduction is associated with elevated amyloid-β PET and tau PET concentrations. Notably, HDAC I reduction mediates the deleterious effects of amyloid-β and tau on brain atrophy and cognitive impairment. HDAC I PET reduction is associated with 2-year longitudinal neurodegeneration and cognitive decline. We also find HDAC I reduction in the postmortem brain tissue of patients with AD and in a transgenic rat model expressing human amyloid-β plus tau pathology in the same brain regions identified in vivo using PET. These observations highlight HDAC I reduction as an element associated with AD pathophysiology. The link between amyloid and tau proteins with Alzheimer's disease progression remains unclear. Here, the authors propose HDACs I downregulation as an element linking the deleterious effects of brain proteinopathies with disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex
- Author
-
Therriault, Joseph, Pascoal, Tharick A., Benedet, Andrea L., Tissot, Cecile, Savard, Melissa, Chamoun, Mira, Lussier, Firoza, Kang, Min Su, Berzgin, Gleb, Wang, Tina, Fernandes-Arias, Jaime, Massarweh, Gassan, Soucy, Jean-Paul, Vitali, Paolo, Saha-Chaudhuri, Paramita, Gauthier, Serge, and Rosa-Neto, Pedro
- Subjects
Male ,Amyloid beta-Peptides ,Apolipoprotein E4 ,Age Factors ,Brain ,tau Proteins ,Middle Aged ,Neuropsychological Tests ,Article ,Cognition ,Sex Factors ,Alzheimer Disease ,Positron-Emission Tomography ,mental disorders ,Humans ,Cognitive Dysfunction ,Female ,Aged - Abstract
Objective To assess the frequency of biologically defined Alzheimer disease (AD) in relation to age, sex, APOE ε4, and clinical diagnosis in a prospective cohort study evaluated with amyloid-PET and tau-PET. Methods We assessed cognitively unimpaired (CU) elderly (n = 166), patients with amnestic mild cognitive impairment (n = 77), and patients with probable AD dementia (n = 62) who underwent evaluation by dementia specialists and neuropsychologists in addition to amyloid-PET with [18F]AZD4694 and tau-PET with [18F]MK6240. Individuals were grouped according to their AD biomarker profile. Positive predictive value for biologically defined AD was assessed in relation to clinical diagnosis. Frequency of AD biomarker profiles was assessed using logistic regressions with odds ratios (ORs) and 95% confidence intervals (CIs). Results The clinical diagnosis of probable AD dementia demonstrated good agreement with biologically defined AD (positive predictive value 85.2%). A total of 7.88% of CU were positive for both amyloid-PET and tau-PET. Frequency of biologically defined AD increased with age (OR 1.14; p < 0.0001) and frequency of APOE ε4 allele carriers (single ε4: OR 3.82; p < 0.0001; double ε4: OR 17.55, p < 0.0001). Conclusion Whereas we observed strong, but not complete, agreement between clinically defined probable AD dementia and biomarker positivity for both β-amyloid and tau, we also observed that biologically defined AD was not rare in CU elderly. Abnormal tau-PET was almost exclusively observed in individuals with abnormal amyloid-PET. Our results highlight that even in tertiary care memory clinics, detailed evaluation by dementia specialists systematically underestimates the frequency of biologically defined AD and related entities. Classification of Evidence This study provides Class I evidence that biologically defined AD (abnormal amyloid PET and tau PET) was observed in 85.2% of people with clinically defined AD and 7.88% of CU elderly.
- Published
- 2020
33. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
- Author
-
Tissot, Cécile, primary, Therriault, Joseph, additional, Pascoal, Tharick A., additional, Chamoun, Mira, additional, Lussier, Firoza Z., additional, Savard, Melissa, additional, Mathotaarachchi, Sulantha S., additional, L. Benedet, Andréa, additional, Thomas, Emilie M., additional, Parsons, Marlee, additional, Nasreddine, Ziad, additional, Rosa‐Neto, Pedro, additional, and Gauthier, Serge, additional
- Published
- 2021
- Full Text
- View/download PDF
34. Determining Amyloid-β Positivity Using 18F-AZD4694 PET Imaging
- Author
-
Therriault, Joseph, primary, Benedet, Andrea L., additional, Pascoal, Tharick A., additional, Savard, Melissa, additional, Ashton, Nicholas J., additional, Chamoun, Mira, additional, Tissot, Cecile, additional, Lussier, Firoza, additional, Kang, Min Su, additional, Bezgin, Gleb, additional, Wang, Tina, additional, Fernandes-Arias, Jaime, additional, Massarweh, Gassan, additional, Vitali, Paolo, additional, Zetterberg, Henrik, additional, Blennow, Kaj, additional, Saha-Chaudhuri, Paramita, additional, Soucy, Jean-Paul, additional, Gauthier, Serge, additional, and Rosa-Neto, Pedro, additional
- Published
- 2020
- Full Text
- View/download PDF
35. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles
- Author
-
Pascoal, Tharick A, primary, Therriault, Joseph, additional, Benedet, Andrea L, additional, Savard, Melissa, additional, Lussier, Firoza Z, additional, Chamoun, Mira, additional, Tissot, Cécile, additional, Qureshi, Muhammad Naveed Iqbal, additional, Kang, Min Su, additional, Mathotaarachchi, Sulantha, additional, Stevenson, Jenna, additional, Hopewell, Robert, additional, Massarweh, Gassan, additional, Soucy, Jean-Paul, additional, Gauthier, Serge, additional, and Rosa-Neto, Pedro, additional
- Published
- 2020
- Full Text
- View/download PDF
36. Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia.
- Author
-
Therriault, Joseph, Pascoal, Tharick A., Sefranek, Marcus, Mathotaarachchi, Sulantha, Benedet, Andrea L., Chamoun, Mira, Lussier, Firoza Z., Tissot, Cécile, Bellaver, Bruna, Lukasewicz, Pamela S., Zimmer, Eduardo R., Saha‐Chaudhuri, Paramita, Gauthier, Serge, and Rosa‐Neto, Pedro
- Subjects
TAU proteins ,DEMENTIA ,AMYLOID plaque ,CINGULATE cortex ,TEMPORAL lobe ,COGNITION disorders - Abstract
Objective: To investigate the relationship between the topography of amyloid‐β plaques, tau neurofibrillary tangles, and the overlap between the two, with cognitive dysfunction in individuals without dementia. Methods: We evaluated 154 individuals who were assessed with amyloid‐β PET with [18F]AZD4694, tau‐PET with [18F]MK6240, structural MRI, and neuropsychological testing. We also evaluated an independent cohort of 240 individuals who were assessed with amyloid‐β PET with [18F]Florbetapir, tau‐PET with [18F]Flortaucipir, structural MRI, and neuropsychological testing. Using the VoxelStats toolbox, we conducted voxel‐wise linear regressions between amyloid‐PET, tau‐PET, and their interaction with cognitive function, correcting for age, sex, and years of education. Results: In both cohorts, we observed that tau‐PET standardized uptake value ratio in medial temporal lobes was associated with clinical dementia rating Sum of Boxes (CDR‐SoB) scores independently of local amyloid‐PET uptake (FWE corrected at p < 0.001). We also observed in both cohorts that in regions of the neocortex, associations between neocortical tau‐PET and clinical function were dependent on local amyloid‐PET (FWE corrected at p < 0.001). Interpretation: In medial temporal brain regions, characterized by the accumulation of tau pathology in the absence of amyloid‐β, tau had direct associations with cognitive dysfunction. In brain regions characterized by the accumulation of both amyloid‐β and tau pathologies such as the posterior cingulate and medial frontal cortices, tau's relationship with cognitive dysfunction was dependent on local amyloid‐β concentrations. Our results provide evidence that amyloid‐β in Alzheimer's disease influences cognition by potentiating the deleterious effects of tau pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. Association of plasma P-tau181 with memory decline in non-demented adults.
- Author
-
Therriault, Joseph, Benedet, Andrea L., Pascoal, Tharick A., Lussier, Firoza Z., Tissot, Cecile, Karikari, Thomas K., Ashton, Nicholas J., Chamoun, Mira, Bezgin, Gleb, Mathotaarachchi, Sulantha, Gauthier, Serge, Saha-Chaudhuri, Paramita, Zetterberg, Henrik, Blennow, Kaj, and Rosa-Neto, Pedro
- Published
- 2021
- Full Text
- View/download PDF
38. Cholinergic Potentiation Alters Perceptual Eye Dominance Plasticity Induced by a Few Hours of Monocular Patching in Adults
- Author
-
Sheynin, Yasha, primary, Chamoun, Mira, additional, Baldwin, Alex S., additional, Rosa-Neto, Pedro, additional, Hess, Robert F., additional, and Vaucher, Elvire, additional
- Published
- 2019
- Full Text
- View/download PDF
39. Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease.
- Author
-
Tissot, Cécile, L. Benedet, Andréa, Therriault, Joseph, Pascoal, Tharick A., Lussier, Firoza Z., Saha-Chaudhuri, Paramita, Chamoun, Mira, Savard, Melissa, Mathotaarachchi, Sulantha S., Bezgin, Gleb, Wang, Yi-Ting, Fernandez Arias, Jaime, Rodriguez, Juan Lantero, Snellman, Anniina, Ashton, Nicholas J., Karikari, Thomas K., Blennow, Kaj, Zetterberg, Henrik, De Villers-Sidani, Etienne, and Huot, Philippe
- Subjects
ALZHEIMER'S disease ,MAGNETIC resonance imaging ,CEREBRAL atrophy ,AGE factors in Alzheimer's disease ,GRAY matter (Nerve tissue) - Abstract
Background: To investigate the association of plasma pTau181, assessed with a new immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and longitudinally, in aging and Alzheimer's disease. Methods: Observational data was obtained from the Alzheimer's Disease Neuroimaging Initiative, in which participants underwent plasma assessment and magnetic resonance imaging. Based on their clinical diagnosis, participants were classified as cognitively unimpaired and cognitively impaired. Linear regressions and linear mixed-effect models were used to test the cross-sectional and longitudinal associations between baseline plasma pTau181 and neurodegeneration using voxel-based morphometry. Results: We observed a negative correlation at baseline between plasma pTau181 and gray matter volume in cognitively unimpaired individuals. In cognitively impaired individuals, we observed a negative association between plasma pTau181 and both gray and white matter volume. In longitudinal analyses conducted in the cognitively unimpaired group, plasma pTau181 was negatively correlated with gray matter volume, starting 36 months after baseline assessments. Finally, in cognitively impaired individuals, plasma pTau181 concentrations were negatively correlated with both gray and white matter volume as early as 12 months after baseline, and neurodegeneration increased in an incremental manner until 48 months. Conclusions: Higher levels of plasma pTau181 correlate with neurodegeneration and predict further brain atrophy in aging and Alzheimer's disease. Plasma pTau181 may be useful in predicting AD-related neurodegeneration, comparable to positron emission tomography or cerebrospinal fluid assessment with high specificity for AD neurodegeneration. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
- Author
-
Benedet, Andréa L, Leuzy, Antoine, Pascoal, Tharick A, Ashton, Nicholas J, Mathotaarachchi, Sulantha, Savard, Melissa, Therriault, Joseph, Kang, Min Su, Chamoun, Mira, Schöll, Michael, Zimmer, Eduardo R, Gauthier, Serge, Labbe, Aurélie, Zetterberg, Henrik, Rosa-Neto, Pedro, Blennow, Kaj, Initiative, for the Alzheimer's Disease Neuroimaging, and Alzheimer’s Disease Neuroimaging Initiative
- Subjects
ALZHEIMER'S disease ,CYTOPLASMIC filaments ,SINGLE molecules ,CEREBRAL atrophy ,MILD cognitive impairment ,CLINICAL drug trials - Abstract
Neurofilament light (NfL) is a marker of neuroaxonal injury, a prominent feature of Alzheimer's disease. It remains uncertain, however, how it relates to amyloid and tau pathology or neurodegeneration across the Alzheimer's disease continuum. The aim of this study was to investigate how plasma NfL relates to amyloid and tau PET and MRI measures of brain atrophy in participants with and without cognitive impairment. We retrospectively examined the association between plasma NfL and MRI measures of grey/white matter volumes in the Alzheimer's Disease Neuroimaging Initiative [ADNI: n = 1149; 382 cognitively unimpaired control subjects and 767 cognitively impaired participants (mild cognitive impairment n = 420, Alzheimer's disease dementia n = 347)]. Longitudinal plasma NfL was measured using single molecule array (Simoa) technology. Cross-sectional associations between plasma NfL and PET amyloid and tau measures were independently assessed in two cohorts: ADNI [n = 198; 110 cognitively unimpaired, 88 cognitively impaired (MCI n = 67, Alzheimer's disease dementia n = 21), data accessed October 2018]; and Translational Biomarkers in Aging and Dementia [TRIAD, n = 116; 74 cognitively unimpaired, 42 cognitively impaired (MCI n = 16, Alzheimer's disease dementia n = 26), data obtained November 2017 to January 2019]. Associations between plasma NfL and imaging-derived measures were examined voxel-wise using linear regression (cross-sectional) and linear mixed effect models (longitudinal). Cross-sectional analyses in both cohorts showed that plasma NfL was associated with PET findings in brain regions typically affected by Alzheimer's disease; associations were specific to amyloid PET in cognitively unimpaired and tau PET in cognitively impaired (P < 0.05). Longitudinal analyses showed that NfL levels were associated with grey/white matter volume loss; grey matter atrophy in cognitively unimpaired was specific to APOE ε4 carriers (P < 0.05). These findings suggest that plasma NfL increases in response to amyloid-related neuronal injury in preclinical stages of Alzheimer's disease, but is related to tau-mediated neurodegeneration in symptomatic patients. As such, plasma NfL may a useful measure to monitor effects in disease-modifying drug trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
41. Determining Amyloid-β positivity using [18F]AZD4694 PET imaging.
- Author
-
Therriault, Joseph, Benedet, Andrea L., Pascoal, Tharick A., Savard, Melissa, Ashton, Nicholas J., Chamoun, Mira, Tissot, Cecile, Lussier, Firoza, Min Su Kang, Bezgin, Gleb, Wang, Tina, Fernandes-Arias, Jaime, Massarweh, Gassan, Vitali, Paolo, Zetterberg, Henrik, Blennow, Kaj, Saha-Chaudhuri, Paramita, Soucy, Jean-Paul, Gauthier, Serge, and Rosa-Neto, Pedro
- Published
- 2020
- Full Text
- View/download PDF
42. Determining Amyloid-β positivity using [18F]AZD4694 PET imaging.
- Author
-
Therriault, Joseph, Benedet, Andrea L., Pascoal, Tharick A., Savard, Melissa, Ashton, Nicholas J., Chamoun, Mira, Tissot, Cecile, Lussier, Firoza, Min Su Kang, Berzgin, Gleb, Wang, Tina, Fernandes-Arias, Jaime, Massarweh, Gassan, Vitali, Paolo, Zetterberg, Henrik, Blennow, Kaj, Saha-Chaudhuri, Paramita, Soucy, Jean-Paul, Gauthier, Serge, and Rosa-Neto, Pedro
- Published
- 2020
- Full Text
- View/download PDF
43. Effet de la stimulation cholinergique sur la perception visuelle chez le rat et l'humain : études comportementales et électrophysiologiques
- Author
-
Chamoun, Mira and Vaucher, Elvire
- Subjects
Perceptual learning ,Apprentissage perceptuel ,Cholinergic stimulation ,Vision ,Acetylcholinesterase inhibitor ,Visual recovery ,Inhibiteurs de l’acétylcholine estérase ,Récupération visuelle ,Stimulation cholinergique - Abstract
Le système cholinergique joue un rôle important dans de nombreuses fonctions cognitives telles que l'attention et l'apprentissage perceptuel. La stimulation pharmacologique du système cholinergique par le donépézil, un inhibiteur de l’acétylcholinestérase, est un moyen efficace pour améliorer les fonctions cognitives et le traitement cortical via les récepteurs muscariniques et nicotiniques. En effet, le donépézil permet l'accumulation d'acétylcholine dans la fente synaptique. Toutefois, l’effet de la stimulation pharmacologique du système cholinergique sur le traitement visuel complexe et l’apprentissage perceptuel n’est pas encore bien défini. L'objectif de cette thèse est d'étudier, d'une part, l'effet de la combinaison d’un entrainement visuel répétitif avec une stimulation cholinergique sur les capacités visuelles chez le rat et l’humain et, d'autre part, l’effet de la stimulation pharmacologique du système cholinergique sur la restauration des capacités visuelles dans un modèle de déficit visuel chez les rats. Nos résultats ont montré qu’un entrainement visuel/cholinergique entraînait : 1) une potentialisation à long terme de la réponse visuelle corticale chez le rat, 2) une récupération plus rapide des capacités visuelles chez la rat suite un écrasement du nerf optique 3) une amélioration de la performance dans une tâche perceptivo-cognitive de haut niveau plus rapide et conservée dans le temps chez les jeunes sujets sains. Le patron d’électroencéphalographie chez le sujet humain pratiquant une tâche d’attention visuelle n’est cependant pas modifié par l’administration d’une dose unique de donépézil. Ensembles, ces résultats soulignent le bénéfice considérable de la combinaison d’une stimulation du système cholinergique lors de l’entrainement visuel répétitif afin d'obtenir des améliorations de la perception visuelle. Cela présente une avenue très intéressante pour la réhabilitation chez les humains., The cholinergic system plays an important role in many cognitive functions such as attention and perceptual learning. Pharmacological stimulation of the cholinergic system via donepezil, an acetylcholinesterase inhibitor, is an efficient tool for enhancing cognitive functions and cortical processing via muscarinic and nicotinic receptors. In fact, donepezil allows the build-up of acetylcholine in the synaptic cleft. However, whether pharmacological manipulation of the cholinergic system has an effect on complex visual processing and perceptual learning remains unclear. The goal of this thesis is to investigate on the one hand the effect of combining repetitive visual training with cholinergic enhancement on visual capacities in rats and humans and on the other hand the effect of the pharmacological stimulation of the cholinergic system on visual restoration in a model of visual deficit in rats. Our results showed that cholinergic potentiation induces 1) a long-term potentiation of visual cortical response following repetitive visual stimulation, 2) a faster recovery of brightness discrimination in rats with an optic nerve crush, 3) a faster progression of and a sustained performance in a highly demanding perceptual-cognitive task for healthy young humans. However, the EEG pattern for subjects performing a visual attention task is not modified by a single administration of donepezil. Together these results underline the substantial benefice of combining cholinergic enhancement with visual training in order to obtain visual perception improvements, which presents an interesting avenue for visual rehabilitation paradigm in humans.
- Published
- 2016
44. Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking
- Author
-
Chamoun, Mira, primary, Huppé-Gourgues, Frédéric, additional, Legault, Isabelle, additional, Rosa-Neto, Pedro, additional, Dumbrava, Daniela, additional, Faubert, Jocelyn, additional, and Vaucher, Elvire, additional
- Published
- 2017
- Full Text
- View/download PDF
45. Cholinergic Potentiation of Restoration of Visual Function after Optic Nerve Damage in Rats
- Author
-
Chamoun, Mira, primary, Sergeeva, Elena G., additional, Henrich-Noack, Petra, additional, Jia, Shaobo, additional, Grigartzik, Lisa, additional, Ma, Jing, additional, You, Qing, additional, Huppé-Gourgues, Frédéric, additional, Sabel, Bernhard A., additional, and Vaucher, Elvire, additional
- Published
- 2017
- Full Text
- View/download PDF
46. Does donepezil improve visual stimuli detection and perceptivo-cognitive performance of heathy young adults ?
- Author
-
Chamoun, Mira, primary, Huppé-Gourgues, Frédéric, additional, Legault, Isabelle, additional, Rosa-Neto, Pedro, additional, Faubert, Jocelyn, additional, and Vaucher, Elvire, additional
- Published
- 2015
- Full Text
- View/download PDF
47. Regulation of the expression of the cholinergic receptors in the visual cortex following long-term enhancement of visual cortical activity by cholinergic stimulation
- Author
-
Groleau, Marianne, primary, Chamoun, Mira, additional, Bhat, Menakshi, additional, Huppé-Gourgues, Frédéric, additional, Couture, Réjean, additional, and Vaucher, Elvire, additional
- Published
- 2015
- Full Text
- View/download PDF
48. In vivo quantification of neurofibrillary tangles with [18F]MK-6240.
- Author
-
Pascoal, Tharick A., Shin, Monica, Kang, Min Su, Chamoun, Mira, Chartrand, Daniel, Mathotaarachchi, Sulantha, Bennacef, Idriss, Therriault, Joseph, Ng, Kok Pin, Hopewell, Robert, Bouhachi, Reda, Hsiao, Hung-Hsin, Benedet, Andrea L., Soucy, Jean-Paul, Massarweh, Gassan, Gauthier, Serge, and Rosa-Neto, Pedro
- Subjects
NEUROFIBRILLARY tangles ,ALZHEIMER'S disease diagnosis ,POSITRON emission tomography ,AUTORADIOGRAPHY ,MILD cognitive impairment ,PATIENTS - Abstract
Background: Imaging agents capable of quantifying the brain's tau aggregates will allow a more precise staging of Alzheimer's disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau imaging agent [
18 F]MK-6240. Methods: In vitro properties of [18 F]MK-6240 were estimated with autoradiography in postmortem brain tissues of 14 subjects (seven AD patients and seven age-matched controls). In vivo quantification of [18 F]MK-6240 binding was performed in 16 subjects (four AD patients, three mild cognitive impairment patients, six healthy elderly individuals, and three healthy young individuals) who underwent 180-min dynamic scans; six subjects had arterial sampling for metabolite correction. Simplified approaches for [18 F]MK-6240 quantification were validated using full kinetic modeling with metabolite-corrected arterial input function. All participants also underwent amyloid-PET and structural magnetic resonance imaging. Results: In vitro [18 F]MK-6240 uptake was higher in AD patients than in age-matched controls in brain regions expected to contain tangles such as the hippocampus, whereas no difference was found in the cerebellar gray matter. In vivo, [18 F]MK-6240 displayed favorable kinetics with rapid brain delivery and washout. The cerebellar gray matter had low binding across individuals, showing potential for use as a reference region. A reversible two-tissue compartment model well described the time–activity curves across individuals and brain regions. Distribution volume ratios using the plasma input and standardized uptake value ratios (SUVRs) calculated after the binding approached equilibrium (90 min) were correlated and higher in mild cognitive impairment or AD dementia patients than in controls. Reliability analysis revealed robust SUVRs calculated from 90 to 110 min, while earlier time points provided inaccurate estimates. Conclusions: This evaluation shows an [18 F]MK-6240 distribution in concordance with postmortem studies and that simplified quantitative approaches such as the SUVR offer valid estimates of neurofibrillary tangle load 90 min post injection. [18 F]MK-6240 is a promising tau tracer with the potential to be applied in the disease diagnosis and assessment of therapeutic interventions. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
49. APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles.
- Author
-
Ferrari-Souza, João Pedro, Lussier, Firoza Z., Leffa, Douglas T., Therriault, Joseph, Tissot, Cécile, Bellaver, Bruna, Ferreira, Pâmela C. L., Malpetti, Maura, Yi-Ting Wang, Povala, Guilherme, Benedet, Andréa L., Ashton, Nicholas J., Chamoun, Mira, Servaes, Stijn, Bezgin, Gleb, Min Su Kang, Stevenson, Jenna, Rahmouni, Nesrine, Pallen, Vanessa, and Poltronetti, Nina Margherita
- Subjects
- *
NEUROFIBRILLARY tangles , *MICROGLIA , *ALZHEIMER'S disease - Abstract
The article presents animal studies suggesting that the apolipoprotein E ε4 (APOEε4) allele as a culprit of early microglial activation in Alzheimer's disease (AD). It mentions the testing of the association between APOEε4 status and microglial activation in living individuals across the aging and AD spectrum.
- Published
- 2023
- Full Text
- View/download PDF
50. Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals.
- Author
-
Woo MS, Tissot C, Lantero-Rodriguez J, Snellman A, Therriault J, Rahmouni N, Macedo AC, Servaes S, Wang YT, Arias JF, Hosseini SA, Chamoun M, Lussier FZ, Benedet AL, Ashton NJ, Karikari TK, Triana-Baltzer G, Kolb HC, Stevenson J, Mayer C, Kobayashi E, Massarweh G, Friese MA, Pascoal TA, Gauthier S, Zetterberg H, Blennow K, and Rosa-Neto P
- Subjects
- Humans, tau Proteins, Cross-Sectional Studies, Amyloid beta-Peptides, Biomarkers, Positron-Emission Tomography, Alzheimer Disease
- Abstract
Introduction: We set out to identify tau PET-positive (A+T+) individuals among amyloid-beta (Aβ) positive participants using plasma biomarkers., Methods: In this cross-sectional study we assessed 234 participants across the AD continuum who were evaluated by amyloid PET with [
18 F]AZD4694 and tau-PET with [18 F]MK6240 and measured plasma levels of total tau, pTau-181, pTau-217, pTau-231, and N-terminal tau (NTA-tau). We evaluated the performances of plasma biomarkers to predict tau positivity in Aβ+ individuals., Results: Highest associations with tau positivity in Aβ+ individuals were found for plasma pTau-217 (AUC [CI95% ] = 0.89 [0.82, 0.96]) and NTA-tau (AUC [CI95% ] = 0.88 [0.91, 0.95]). Combining pTau-217 and NTA-tau resulted in the strongest agreement (Cohen's Kappa = 0.74, CI95% = 0.57/0.90, sensitivity = 92%, specificity = 81%) with PET for classifying tau positivity., Discussion: The potential for identifying tau accumulation in later Braak stages will be useful for patient stratification and prognostication in treatment trials and in clinical practice., Highlights: We found that in a cohort without pre-selection pTau-181, pTau-217, and NTA-tau showed the highest association with tau PET positivity. We found that in Aβ+ individuals pTau-217 and NTA-tau showed the highest association with tau PET positivity. Combining pTau-217 and NTA-tau resulted in the strongest agreement with the tau PET-based classification., (© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.